Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6175360 | 0.86 | ROCK1 (0.51) | MAPK14ROCK1RAB9ANPC1KDM4E | |
| SCHEMBL6178252 | 0.86 | TRPV1 (0.47) | MAPK14ROCK1RAB9AHPGDNPC1 | |
| SCHEMBL6180515 | 0.83 | MAPK14 (0.55) | MAPK14ROCK1HPGDALDH1A1CYP1A2 | |
| SCHEMBL4343331 | 0.82 | MAPK14 (0.71) | MAPK14ROCK1KDM4EMAPTADORA1 | |
| SCHEMBL6177661 | 0.81 | MAPK14 (0.57) | MAPK14ROCK1RAB9ANPC1TSHR | |
| SCHEMBL4332784 | 0.80 | MAPK14 (0.69) | MAPK14ROCK1RAB9AHPGDNPC1 | |
| SCHEMBL6176832 | 0.76 | MAPK14 (0.63) | MAPK14ROCK1KDM4EMAPT | |
| SCHEMBL6179169 | 0.76 | MAPK14 (0.63) | MAPK14ROCK1KDM4EGAAMAPT | |
| SCHEMBL6028582 | 0.76 | KDM4E (0.42) | MAPK14RAB9ANPC1PKMKDM4E | |
| SCHEMBL6180478 | 0.76 | MAPK14 (0.60) | MAPK14ROCK1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | claimed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | claimed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2044957-A1 | TREATMENT AGENT FOR INFLAMMATORY BOWEL DISEASE | ASKA Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| EP-1142890-B1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG CO LTD (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-6511997-B1 | For treatment of a disease associated with tumor necrosis factor alpha, interleukin 1, interleukin 6 or cyclooxygenase II; such as irritable bowel disease | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2003-01-28 | — | — | US | disclosed |
| EP-1142890-A1 | AMINOPYRAZOLE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192164-A1 | Treating agent of inflammatory bowel disease | MAPK6, SLC10A2, MAP3K6 | MAPK14 13/4885ROCK1 637/4885RAB9A 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.